Literature DB >> 1379257

Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery.

M L Davenport1, W L Isley, J B Pucilowska, L B Pemberton, B Lyman, L E Underwood, D R Clemmons.   

Abstract

The insulin-like growth factors (IGFs) are bound to several binding proteins (IGFBPs) that appear to regulate IGF transport, receptor binding, and action. The concentrations of these peptides are altered by catabolic conditions. To determine if IGF-I and IGFBP levels change after surgery, sera were obtained from 16 patients before and after cholecystectomy. Immunoreactive IGF-I measured in plasma samples from which IGFBPs had been extracted did not change postoperatively. In contrast, IGF-I determined in unextracted samples increased roughly 3-fold postoperatively, presumably due to changes in IGFBPs. Two days postoperatively, IGFBP-3 levels, determined by ligand blot, averaged 36% of preoperative values, whereas levels of IGFBP-2 and a 24,000 mol wt IGFBP did not change significantly. Similarly, by immunoblot, intact IGFBP-3 was decreased 84.2 +/- 20.2%, and a 31,000 mol wt IGFBP-3 fragment increased 57.5 +/- 47.4% postoperatively. Coincubation of postoperative, but not preoperative, sera with control sera resulted in a significant decrease in IGFBP-3 and production of proteolytic fragments. IGFBP-3 proteolytic activity in postoperative sera was markedly inhibited by antipain, Na-p-tosyl-L-lysine chloromethyl ketone, phenylmethylsulfonylfluoride, aprotinin, o-phenanthroline, and EDTA, but not by leupeptin or N-tosyl-L-phenylalanine chloromethyl ketone. This pattern of inhibition is consistent with a metal-dependent trypsin-like serine protease. We speculate that proteolysis of IGFBP-3 may alter tissue uptake of IGF-I and thereby help to counteract the catabolic state caused by surgery.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1379257     DOI: 10.1210/jcem.75.2.1379257

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

1.  Direct measurement of IGF-I and IGFBP-3 in bronchoalveolar lavage fluid from idiopathic pulmonary fibrosis.

Authors:  L Pala; S Giannini; E Rosi; B Cresci; G Scano; S Mohan; R Duranti; C M Rotella
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

Review 2.  IGFBP-3. Functional and structural implications in aging and wasting syndromes.

Authors:  M C Gelato; R A Frost
Journal:  Endocrine       Date:  1997-08       Impact factor: 3.633

3.  Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3.

Authors:  M Harrela; H Koistinen; J Kaprio; M Lehtovirta; J Tuomilehto; J Eriksson; L Toivanen; M Koskenvuo; P Leinonen; R Koistinen; M Seppälä
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

4.  In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells.

Authors:  C Blat; J Villaudy; M Binoux
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

Review 5.  Growth and puberty in children with HIV infection.

Authors:  E S Majaliwa; A Mohn; F Chiarelli
Journal:  J Endocrinol Invest       Date:  2009-01       Impact factor: 4.256

6.  Amino acid infusion during anesthesia attenuates the surgery induced decline in IGF-1 and diminishes the "diabetes of injury".

Authors:  Mats K E B Wallin; Eva Selldén; Staffan Eksborg; Kerstin Brismar
Journal:  Nutr Metab (Lond)       Date:  2007-01-09       Impact factor: 4.169

7.  Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers.

Authors:  N P Michell; M J Langman; M C Eggo
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 8.  The Retinol Circulating Complex Releases Hormonal Ligands During Acute Stress Disorders.

Authors:  Yves Ingenbleek
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-04       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.